If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNetscientific Regulatory News (NSCI)

Share Price Information for Netscientific (NSCI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 63.50
Bid: 62.00
Ask: 65.00
Change: 1.00 (1.60%)
Spread: 3.00 (4.839%)
Open: 62.50
High: 63.50
Low: 62.50
Prev. Close: 62.50
NSCI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Grant of Options, Issue of Shares, Director/PDMR

3 Jul 2023 07:00

RNS Number : 6560E
NetScientific PLC
03 July 2023
 

 

 

NetScientific plc

("NetScientific" or the "Company")

 

Grant of Options, Issue of Shares, Director/PDMR Shareholding and Total Voting Rights

 

 

NetScientific Plc (AIM: NSCI), the deep tech and life sciences VC investment group, announces that it has granted a total of 579,703 new options (New Options) to subscribe for ordinary shares in the capital of the Company (Ordinary Shares) to certain of its directors, as detailed below. In addition, certain of its directors have subscribed for and purchased shares in the Company, as detailed below.

 

Grant of new options

In line with the Company's remuneration policy, the Remuneration Committee has approved the award of the following New Options to the directors referred to below in connection with their recent appointments and roles:

Director

New Options

Total options held (including existing options)

Ed Hooper, Executive Director

460,656

565,656

Dr Charles Spicer, Chair

95,238

95,238

Dr Jonathan Robinson, Senior Independent Director

23,809

69,610

 

The New Options were granted under the NetScientific Share Option Scheme, pursuant to which options over a total of 2,310,095 Ordinary Shares have now been granted (excluding lapsed options but including exercised options), representing approximately 9.82 per cent. of the Enlarged Issued Share Capital (as defined below). The maximum potential dilution arising from options awarded under the NetScientific Share Option Scheme remains below the upper limit of 10 per cent. under the rules of the plan.

 

The New Options have an exercise price of 63 pence per share, which is equal to the average of the closing market quotations for Ordinary Shares over the five dealing days prior to the date on which the New Options were granted (the latter being the minimum price that could have been set).

 

The New Options will vest as to one third on the date of grant, as to a further third on the first anniversary of the date of grant and as to the final third on the second anniversary of the date of grant. The New Options may not be exercised earlier than the third anniversary of the date of grant and lapse 10 years after the date of grant (if not sooner in accordance with the terms of the NetScientific Share Option Scheme rules).

 

The FCA notification, made in accordance with the requirements of the EU Market Abuse Regulation, is appended below.

 

Issue of new Ordinary Shares

 

Ed Hooper has chosen to receive payment in the form of 40,000 new Ordinary Shares (New Shares), rather than cash, in respect of c.77.5 per cent. of the annual bonus awarded to him (on a projected net of tax basis) for the year ended 31 December 2023. The new Ordinary Shares are being issued at a price of £0.63 per share, being determined on the same basis as described above in respect of the New Options.

 

Application will be made for the New Ordinary Shares to be admitted to trading on AIM and it is expected that admission will take place on or around 7 July 2023 (Admission). The New Shares will rank pari passu in all respects with the Company's existing ordinary shares.

 

Purchase of Ordinary Shares

 

On 30 June 2023 the following directors purchased shares in the Company through their Self Invested Personal Pensions, as detailed below (Director Dealings).

 

Director

Number of Ordinary Shares acquired

Total number of Ordinary Shares in which interested

% of Enlarged Issued Share Capital

Ed Hooper, Executive Director

20,000

60,000

0.26

Dr Charles Spicer, Chair

16,286

16,286

0.07

 

Total Voting Rights 

 

Upon Admission, the issued share capital of the Company will consist of 23,528,148 Ordinary Shares (Enlarged Issued Share Capital). The Company does not hold any shares in treasury. Therefore, the total number of voting rights in the Company from Admission will be 23,528,148. This figure may be used by shareholders as the denominator for the calculations by which they determine if they are required to notify their interest in or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The information below, set out in accordance with the requirements of the UK Market Abuse Regulation, provides further detail on the grant of options to PDMRs, the issue of the New Shares and the Director Dealings.

 

NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

460,656 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Charles Spicer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

95,238 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Jonathan Robinson

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Options over Ordinary Shares

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Grant of options

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

23,809 options

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

Outside a trading venue

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Subscription for new Ordinary Shares

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.63

40,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Mr Edward Hooper

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.5962

20,000 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

 

Name

 

 

Dr. Charles Spicer

2

 

Reason for the notification

 

a)

 

Position/status

 

 

Director

b)

 

Initial notification /Amendment

 

 

Initial Notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

 

a)

 

Name

 

 

NetScientific plc

b)

 

LEI

 

 

213800N5WD46G1Y7I458

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

 

 

a)

 

Description of the financial instrument, type of instrument

 

Identification code

Ordinary Shares of £0.05 each

 

 

 

GB00BN4R5Q82

b)

 

Nature of the transaction

 

 

Purchase of Ordinary Shares into SIPP

c)

 

Price(s) and volume(s)

 

 

 

Price(s)

 

Volume(s)

£0.614

16,286 Ordinary Shares

 

 

d)

 

Aggregated information

 

 

- Aggregated volume

 

 

- Price

 

 

 

 

 

N/A

 

e)

 

Date of the transaction

 

 

30 June 2023

f)

 

Place of the transaction

 

 

UK AIM

 

 

# # #

 

For more information, please contact:

NetScientific

Ilian Iliev, CEO

Via Belvedere Communications

 

 

WH Ireland (NOMAD, Financial Adviser and Broker)

 

Chris Fielding / Darshan Patel / Enzo Aliaj

+44 (0)20 7220 1666

Belvedere Communications

John West / Llew Angus

 

+44 (0)20 3008 6867

 

About NetScientific

NetScientific plc (AIM: NSCI) is deep tech and life sciences VC investment group with an international portfolio of innovative companies.

NetScientific identifies, invests in, and builds high growth companies in the UK and internationally. The company adds value through the proactive management of its portfolio, progressing to key value inflection points, and delivering investment returns through partial or full liquidity events.

NetScientific differentiates itself by employing a capital-light investment approach, making judicial use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital. The group secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a lean structure that can support a large portfolio.

NetScientific is headquartered in London, United Kingdom, and is admitted to trading on AIM, a market operated by the London Stock Exchange.

www.netscientific.net

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDBGDRBBGDGXD
Date   Source Headline
26th Oct 201612:30 pmRNSVortex Biosciences Appoints Non-Executive Director
30th Sep 20167:00 amRNSProAxsis Gains CE Mark for its Respiratory Test
27th Sep 20167:00 amRNSNetScientific Interim Results
23rd Sep 20167:00 amRNSWanda Technology Selected by 24Hr HomeCare
12th Sep 20167:00 amRNSGlycotest strengthens IP portfolio
8th Sep 20167:00 amRNSWanda Appoints Digital Health Non-Exec Director
6th Sep 20167:00 amRNSNotice of Interim Results
19th Aug 20167:00 amRNSWanda Launches First Consumer App
18th Aug 20167:06 amRNSVortex Biosciences Appoints Experts to New SAB
3rd Aug 20167:00 amRNSVortex Licenses Patents From Harvard University
28th Jul 20167:00 amRNSChange of Adviser
27th Jul 20167:00 amRNSWanda Appoints Medical Director
22nd Jul 20167:00 amRNSA to Z Home Health Care selects Wanda technologies
27th Jun 20167:00 amRNSGrant of Options to Director
15th Jun 20162:13 pmRNSResult of AGM
14th Jun 20167:00 amRNSVortex Biosciences appoints Chairman of SAB
14th Jun 20167:00 amRNSNetScientific hosts Capital Markets Day
10th Jun 20167:30 amRNSConfirmed Start Date for Ian Postlethwaite as CFO
7th Jun 20167:00 amRNSPortfolio PDS Biotechnology presents at BIO 2016
23rd May 20169:00 amRNSNotice of AGM
18th Apr 20167:00 amRNSNetScientific's Vortex presents data at AACR
13th Apr 20167:00 amRNSPDS Biotechnology Reports Positive Phase 1 Results
7th Apr 20167:00 amRNSAnnual Financial Report
5th Apr 20167:00 amRNSNetscientific Appoints Ian Postlethwaite as CFO
30th Mar 20167:00 amRNSProAxsis Forms Scientific Advisory Board
24th Mar 20167:00 amRNSNotice of Results
16th Mar 20167:00 amRNSWanda Forms Scientific Advisory Board
7th Mar 20162:00 pmRNSAdoption of reduced disclosure framework
1st Mar 20161:00 pmRNSVortex co-founder receives US Presidential award
29th Feb 20167:00 amRNSWanda and Dignity Health launch OncoVerse platform
17th Feb 20167:00 amRNSNetScientific appoints Prof. Stephen Smith as NED
9th Feb 201611:05 amRNSPDS Biotechnology partners with NCI
8th Feb 20163:14 pmRNSGrant of Options to Director
26th Jan 20167:00 amRNSDirectorate Change
20th Jan 201611:09 amRNSPDS Biotechnology adds drug development executives
6th Jan 20167:00 amRNSGlycotest Inc. appoints medical advisory board
4th Jan 20167:00 amRNSWANDA signs contract with HRS
16th Dec 20157:00 amRNSLawrence Cohen appointed as CEO of Glycotest Inc.
14th Dec 20157:00 amRNSAppointment of Gene Walther as Vortex CEO
3rd Dec 20157:00 amRNSProAxsis' ProteaseTagT research update
30th Nov 20157:00 amRNSProAxsis presents data to validate its immunoassay
16th Nov 20157:00 amRNSIssue of Equity
11th Nov 20157:00 amRNSHolding(s) in Company
10th Nov 20157:00 amRNSGrant of Options
6th Nov 201512:14 pmRNSResult of General Meeting
3rd Nov 20154:29 pmRNSHolding(s) in Company
21st Oct 20151:52 pmRNSPosting of Circular
1st Oct 20157:00 amRNSProposed Placing and Fund Raising to raise c.£20m
1st Oct 20157:00 amRNSHalf Yearly Report
18th Sep 20157:00 amRNSDivestment of Shareholding in Frontier BioSciences

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.